Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
95 hedge funds and large institutions have $391M invested in Adamas Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 6 closing their positions.
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
42% more capital invested
Capital invested by funds: $276M → $391M (+$115M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more funds holding
Funds holding: 77 → 95 (+18)
11% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 27
4% less call options, than puts
Call options by funds: $8.72M | Put options by funds: $9.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$16.9M |
| 2 |
KA
Kerrisdale Advisers
Miami,
Florida
|
+$14M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$13.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$35.9M |
| 2 |
AC
Armistice Capital
New York
|
-$7.48M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.07M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5M |
| 5 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$4.33M |
ADMS Hedge Fund Activity: Q3 2017 in Review
95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2017, worth a combined $391M — up 42% from $276M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ADMS positions and 6 closed out — a net gain of 19 holders — while 30 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, adding an estimated $16.9M. The largest seller was Great Point Partners, cutting an estimated $35.9M.
- 95 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2017, up from 77 in Q2 2017.
- Funds reported $391M of Adamas Pharmaceuticals stock for Q3 2017, up 42% quarter-over-quarter.
- 25 funds opened new Adamas Pharmaceuticals positions in Q3 2017 and 6 closed out, a net change of +19 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2017 was Millennium Management, an estimated $16.9M added.
- The largest Adamas Pharmaceuticals seller in Q3 2017 was Great Point Partners, an estimated $35.9M sold.
Based on aggregated 13F filings for Q3 2017.